Prof. Tiebang Kang is a deputy chair of Dept of Experimental Research, and a principle investigator and professor of Sun Yat-sen University Cancer Center. He gained his Ph.D. degree at Bielefeld University in 2003 and had his Post-doc training in MD Anderson Cancer Center and Washington University in St. Louis from 2004 to 2008. Dr. Kang moved back to China to start his lab in 2008. Dr. Kang was awarded as a Distinguished Professor from NCSF and Ministry of Education of China in 2011 and 2014, respectively. In 2019, Dr. Kang was awarded as a Distinguished Scholar Professor of Guangdong province.

Dr. Kang’s laboratory majorly engages in the cell cycle regulation, exosomes and metastasis. The main theme in his lab is to identify new targets to overcome the drug resistance for cancer treatments and/or to improve the outcomes of cancer patients with metastases, and to illustrate how these targets execute their intracellular functions and/or their secretion into exosomes to modulate the tumor microenvironment.

1992   Clinical laboratory Medicine
Hunan Medical University, Changsha, China

1996  M.S. in Biochemistry
Guangdong Medical College, Zhanjiang, China

2003  Ph.D. in Biochemistry
Bielefeld University, Germany

2004-2008  Postdoc in Molecular Oncology
MD Anderson Cancer Center and Washington University in St. Louis, USA

10 representative publications:
1. Wei D#, Zhan W#, Gao Y#, Huang L, Gong R, Wang W, Zhang R, Wu Y, Gao S, Kang T* RAB31 marks and controls an ESCRT-independent exosome pathway. Cell Res. 2021 Feb, 31(2), 157–177.（IF: 20.50）

2. Zhong L#, Liao D#, Li J#, Liu W, Wang J, Zeng C, Wang X, Cao Z, Zhang R, Li M, Jiang K, Zeng YX, Sui J*, Kang T*. Rab22a-NeoF1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes. Signal Transduct Target Ther. 2021 Feb 11; 6(1):59.（IF: 13.49）

3. Liao D#, Zhong L#, Yin J#, Zeng C, Wang X, Huang X, Chen J, Zhang H, Zhang R, Guan XY, Shuai X, Sui J, Gao S, Deng W, Zeng YX, Shen J*, Chen J*, Kang T* Chromosomal Translocation-derived Aberrant RAB22A Drives Osteosarcoma Metastasis. Nature Cell Biol, July 2020, 22, 868–881.（IF: 20.04）

4. Zhou L, Zheng L, Hu K, Wang X, Zhang R, Zou Y, Zhong L, Wang S, Wu Y*, Kang T* SUMOylation Stabilizes hSSB1 and Enhances the Recruitment of NBS1 to DNA Damage Sites. Signal Transduct Target Ther. 2020 Jun 24; 5(1):80.（IF: 13.49）

5. Wang x, Qin G, Liang X, Wang Z, Liao D, Zhong L, Zhang R, Zeng YX, Wu Y*, Kang T* Targeting the CK1α/CBX4 Axis for Metastasis in Osteosarcoma. Nat Commun, 2020 Feb 28; 11, 1141.（IF:12.12）

6. Liao D, Zhong L, Duan T, Zhang RH, Wang X, Wang G, Hu K, Lv X, Kang T* Aspirin suppresses the growth and metastasis of osteosarcoma through the NF-kB pathway. Clin Cancer Res, 2015 Dec 1; 21, 5349-59.（IF: 10.10） 

7. Wu Y#, Chen H#, Lu J, Zhang M, Zhang R, Duan T, Wang X, Huang J*, Kang T* Acetylation-dependent function of human single-stranded DNA binding protein 1(hSSB1). Nucleic Acids Res. 2015 Sep 18; 43(16):7878-87.（IF: 11.50）

8. Xu S#, Wu Y#, Chen Q, Cao J, Hu K, Tang J, Sang Y, Lai F, Wang L, Zhang R, Li S-P, Zeng Y-X, Yin Y, Kang T* hSSB1 regulates both the stability and the transcriptional activity of p53. Cell Res. 2013 Mar; 23(3): 423-35.（IF: 20.50）

9. Hong J#, Hu K#, Yuan Y*, Sang Y, Bu Q, Chen G, Yang L, Li B, Huang P, Chen D1, Liang Y, Zhang R, Pan J, Zeng YX, Kang T* Chk1 Targets Spleen Tyrosine Kinase (L) for Proteolysis in Hepatocellular Carcinoma. J Clin Invest. 2012 Jun; 122(6): 2165-75.（IF: 11.86）

10. Tang QL#, Xie XB#, Wang J#, Chen Q, Han AJ, Zou CY, Yin JQ, Liu DW, Liang Y, Zhao ZQ, Yong BC, Zhang RH, Feng QS, Deng WD, Zhu XF, Zhou BP, Zeng YX1, Shen JN*, and Kang T* Glycogen Synthase Kinase-3β, NF-κB Signaling, and Tumorigenesis of Osteosarcoma. J Natl Cancer Inst. 2012 May 16; 104(10): 749-63.（IF: 11.57）

Updated March 2021